No abstract

No abstract

A135female; 48% control patients. Overall, 15.8% of patients experienced hyperkalemia: 9.8% had ≥ 1 mild hyperkalemia event and 6.1% had moderate/severe events. 8.5% of control patients experienced hyperkalemia events compared with 23.5% of patients with HF, 29.5% of patients with CKD stages 3-4, and 47.6% of patients with HF and CKD stages 3-4. Hyperkalemia was more prevalent in patients with each measured comorbidity compared to control patients, and its severity increased with CKD severity (all comparisons, P< 0.0001). Moderate/severe hyperkalemia was more prevalent in patients with later-stage CKD compared to patients with earlier stage kidney disease. Prevalence of hyperkalemia was generally higher in patients aged ≥ 65 years than in similarly comorbid patients aged < 65 years. ConClusions: A retrospective analysis of electronic medical record data demonstrated that hyperkalemia was more common in patients with HF and/or CKD -especially in those with more advanced diseasethan in patients without these comorbidities. objeCtives: describe the national prevalence of deep vein thrombosis (DVT) and pulmonary embolism (PE), among patients hospitalized in private and public French hospitals and to compare it to those described in US Hospitals. Methods: The statistics are from the national PMSI MCO databases inspired by the US Medicare system. Data are encoded using ICD10. The codes used for VTE are I801 to I809 for DVT and codes I260, I269 for PE. The analyses identify all VTE, DVT without PE (DVT) and PE with or without previous/associated DVT. The study data cover the period 2005 to 2011. The French data are compared to those issued in the Morbidity, Mortality Weekly Report of the Centre for Disease Control and Prevention. Results: Data from the national database reveal that over the period 2005 to 2011 the incidence of hospital stays came to 860 343 (1.09%) for VTE, with 428 261 (0.543%) for DVT without PE and 432 082 (0.548%) for PE. The mean number of VTE hospitalized per year over the period was 122 906, including 61 180 for DVT and 61 726 for PE. Out of the French population > 18y, those 122 906 VTE correspond to an incidence of 247 hospitalizations for 100 000 vs. 239 in the USA for the VTE, of 124 vs. 118 for the DVT without EP and of 123 vs. 121 for the EP which is very similar. These instances of VTE occurred in France for 43.4% in men vs. 45.8% in the USA and 56.6% vs.54.2% in women. ConClusions: French VTE incidence is high and similar to those described in the USA. These results point out an alarming situation that questions the quality of prevention and/or its effectiveness. VTE prevention policies must be strengthened in hospitals for the sake of patients and healthcare savings alike. PCV35The PreValenCe and odds-raTios oF selF-rePorTed diagnosis oF hyPerTension among us adulTs by raCial/eThniC subgrouPs, examining The JoinT eFFeCT oF mulTiPle risk FaCTors: naTional healTh inTerView surVey,

No abstract

This had the inherent limitations associated with a retrospective chart review; because data was initially collected for clinical rather than research purposes, certain information may have been absent, incomplete, or missed by data abstractors.

The Patient Protection and Affordable Care Act (PPACA) has considerably transformed the approaches being used to deliver health care in the United States. It was enacted to expand health insurance access, improve funding for health professions education, and reform patient care delivery. The traditional fee-for-service payment system has been criticized for overspending and providing substandard quality of care. The Accountable Care Organization (ACO) was developed as a payment reform mechanism to slow rising health care costs and improve quality. Under this concept, networks of clinicians and hospitals share responsibility for a population of patients and are held accountable for the fi nancial and clinical outcomes. Due to high rates of medication misuse, nonadherence to therapeutic medication regimens, and preventable adverse drug events, pharmacists are in an ideal position to manage drug therapy and reduce health care expenditures; as such, they may be valuable assets to the ACO team. This article discusses the role of the pharmacist in the era of ACOs specifi cally and health care reform globally. It outlines pharmacy-related quality of care measures, medication therapy management (MTM) programs (which may provide the foundation for pharmacist involvement in ACOs), and pharmacist functions in patient-centered medical homes (through which ACO services may be organized). The article concludes with a description of successful ACO models that have incorporated pharmacists into their programs.

No abstract

At a single hospital, wide variation in enoxaparin prescribing patterns existed. Further study is necessary to elucidate more fully the appropriate dosing strategy for this agent in the treatment of atrial fibrillation.